Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France (RosaLEE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05697146 |
|
Recruitment Status :
Recruiting
First Posted : January 25, 2023
Last Update Posted : April 15, 2024
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is a national, multicenter, prospective, non-interventional study in women with HR+/HER2- locally advanced or metastatic breast cancer (BC), for which a prior clinical decision to initiate ribociclib + endocrine therapy (ET) treatment according to the marketing authorization has been taken and was taken independent and prior to study participation decision.
| Condition or disease | Intervention/treatment |
|---|---|
| Breast Cancer | Other: ribociclib + ET |
Included patients will be followed until the end of study, death or lost to follow-up even if ribociclib and ET are discontinued. The end of the study is defined as 3 years after the first visit of the last patient included (Last Patient First Visit [LPFV]). The total duration of the study will be 4 years and half (18 months of inclusion + 3 years of follow-up). Thus, a patient included at the beginning of the inclusion period will be followed for 4 years and half and a patient included at the end of the inclusion period will be followed for at least 3 years.
| Study Type : | Observational |
| Estimated Enrollment : | 482 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study |
| Actual Study Start Date : | December 13, 2022 |
| Estimated Primary Completion Date : | June 28, 2027 |
| Estimated Study Completion Date : | June 28, 2027 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Breast cancer
MedlinePlus related topics:
Breast Cancer
Drug Information
available for:
Ribociclib
| Group/Cohort | Intervention/treatment |
|---|---|
|
ribociclib + ET
Women prescribed ribociclib + Endocrine Therapy (ET)
|
Other: ribociclib + ET
There is no treatment allocation. Patients administered ribociclib + endocrine Therapy (ET) by prescription will be enrolled. |
Primary Outcome Measures :
- Proportion of patients by initial dose of ribociclib [ Time Frame: Baseline ]Proportion of patients by initial dose of ribociclib to be collected
- Proportion of patients by endocrine therapy partner [ Time Frame: Baseline, up to 54 months ]Proportion of patients by endocrine therapy partner to be collected(e.g., tamoxifen, letrozole, fulvestrant, anastrozole, exemestane, LHRH agonist)
- Proportion of patients for each line of treatment with ribociclib [ Time Frame: Baseline ]Proportion of patients for each line of treatment with ribociclib (1L, 2L, >2L) to be collected
Secondary Outcome Measures :
- Progression Free Survival (PFS) by treatment line and endocrine partner [ Time Frame: month 12, month 24, month 36, up to 54 months ]Progression free survival (PFS): time from the date of treatment initiation with ribociclib to the date of the first documented disease progression or death due to any cause, whichever occurs first; if a patient has not had an event, the PFS will be censored at the date of the last adequate tumor assessment (RECIST 1.1).
- Overall Survival (OS) [ Time Frame: month 12, month 24, month 36, up to 54 months ]Overall survival: time from the date of treatment initiation with ribociclib until death due to any cause; if a patient is not known to have died, then the OS will be censored at the latest date the patient was known to be alive.
- Identify prognostic factors influencing the OS and PFS [ Time Frame: Up to 54 months ]Prognostic factors influencing the OS and PFS will be listed
- Proportion of patients with adjuvant treatment and type of treatment [ Time Frame: Up to 54 months ]Proportion of patients with adjuvant treatment and type of treatment to be collected
- Proportion of patients treated with chemotherapy/ET/targeted therapy and type of local treatment [ Time Frame: Up to 54 months ]Proportion of patients treated with chemotherapy/ET/targeted therapy and type of local treatment to be collected
- Proportion of patients by menopausal status [ Time Frame: Up to 54 months ]Proportion of patients by menopausal status (pre-/perimenopausal patients versus postmenopausal patients)
- Proportion of de novo metastatic patients, 1L, 2L and >2L at ribociclib initiation [ Time Frame: Up to 54 months ]Proportion of de novo metastatic patients, 1L, 2L and >2L at ribociclib initiation to be collected
- Proportion of patients with complete response (CR)/partial response (PR)/stable disease (SD)/progressive disease (PD)/unknown [ Time Frame: Up to 54 months ]Proportion of patients with complete response (CR)/partial response (PR)/stable disease (SD)/progressive disease (PD)/unknown to be collected
- Overall response rate [ Time Frame: Up to 54 months ]Overall response rate, defined as the proportion of patients with best overall response or complete response (CR) or partial response (PR) according to RECIST 1.1.
- In the subgroup of patients with visceral metastasis: median PFS [ Time Frame: Up to 54 months ]Progression free survival (PFS): time from the date of treatment initiation with ribociclib to the date of the first documented disease progression or death due to any cause, whichever occurs first; if a patient has not had an event, the PFS will be censored at the date of the last adequate tumor assessment (RECIST 1.1).
- In the subgroup of patients with visceral metastasis: PFS rate [ Time Frame: Up to 54 months ]Progression free survival (PFS): time from the date of treatment initiation with ribociclib to the date of the first documented disease progression or death due to any cause, whichever occurs first; if a patient has not had an event, the PFS will be censored at the date of the last adequate tumor assessment (RECIST 1.1).
- In the subgroup of patients with visceral metastasis: median OS [ Time Frame: Up to 54 months ]Overall survival: time from the date of treatment initiation with ribociclib until death due to any cause; if a patient is not known to have died, then the OS will be censored at the latest date the patient was known to be alive.
- In the subgroup of patients with visceral metastasis: OS rate [ Time Frame: Up to 54 months ]Overall survival: time from the date of treatment initiation with ribociclib until death due to any cause; if a patient is not known to have died, then the OS will be censored at the latest date the patient was known to be alive.
- In the subgroup of patients with visceral metastasis: proportion of patients with CR/PR/SD/PD/unknown [ Time Frame: Up to 54 months ]In the subgroup of patients with visceral metastasis: proportion of patients with complete response (CR)/partial response (PR)/stable disease (SD)/progressive disease (PD)/unknown to be collected
- Sequential PFS (S-PFS) [ Time Frame: month 12, month 24, month 36, up to 54 months ]Sequential progression free survival: time from the date of treatment initiation with ribociclib to the date of the second and subsequent documented progression or death due to any cause, whichever occurs first.
- Time to chemotherapy since ribociclib initiation [ Time Frame: Up to 54 months ]Time to chemotherapy since ribociclib initiation to be collected
- Proportion of patients with ribociclib dose adjustment after treatment initiation and reason(s) [ Time Frame: Up to 54 months ]Proportion of patients with ribociclib dose adjustment after treatment initiation; adjustment type (dose modifications/interruptions during treatment) and reason(s) for dose modifications/interruptions).
- Treatment exposure to ribociclib [ Time Frame: Up to 54 months ]Treatment exposure to ribociclib: time from treatment initiation to treatment discontinuation.
- Reason(s) for discontinuation [ Time Frame: Up to 54 months ]Treatment discontinuation: permanent cessation of the treatment received, for any reason.
- In the subgroup of oligometastatic patients at inclusion: proportion of patients treated with local treatment [ Time Frame: Up to 54 months ]In the subgroup of oligometastatic patients at inclusion: proportion of patients treated with local treatment and treatment outcome to be collected
- Proportion of visits in the site versus proportion of remote visits [ Time Frame: Up to 54 months ]Proportion of visits in the site versus proportion of remote visits to be collected
- Proportion of patients with at least one hospitalization [ Time Frame: Up to 54 months ]Proportion of patients with at least one hospitalization to be collected
- EuroQol 5-Dimension Questionnaire5-level version (EQ-5D-5L) scores [ Time Frame: Up to 54 months ]EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3=moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Pre-/perimenopausal and postmenopausal women with HR+/HER2- advanced or metastatic breast cancer |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Advanced HR+/HER2- breast cancer population treated with ribociclib in France
Criteria
Inclusion Criteria:
Patients who meet all of the following criteria will be included in the RosaLEE study:
- Adult women aged ≥ 18 years old at inclusion.
- Pre-/Peri-/Postmenopausal women with locally advanced or metastatic HR+/HER2- BC.
- Prior clinical decision (independent of study participation)to initiate ribociclib + ET treatment according to the marketing authorization.
- Patients having given their non-objection to participate in the study.
- Patients presenting with medical conditions to be treated with ribociclib + ET according to the summary of product characteristics.
Exclusion Criteria:
- Patients for whom ribociclib + AI in treatment combination has been initiated before inclusion.
- Patients for whom ribociclib + fulvestrant in treatment combination has been initiated before inclusion.
- Patients for whom AI or fulvestrant in monotherapy has been initiated > 28 days before inclusion.
- Participation in any clinical study involving investigational therapy except for the Trans-RosaLEE study, conducted by the IPC.
- Patient who is pregnant or has expressed desire for pregnancy during Ribociclib treatment.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05697146
Contacts
| Contact: Novartis Pharmaceuticals | +41613241111 | novartis.email@novartis.com | |
| Contact: Novartis Pharmaceuticals |
Locations
Show 68 study locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT05697146 |
| Other Study ID Numbers: |
CLEE011AFR01 |
| First Posted: | January 25, 2023 Key Record Dates |
| Last Update Posted: | April 15, 2024 |
| Last Verified: | April 2024 |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
|
HR+/HER2- advanced or metastatic breast cancer RosaLEE NIS France Ribociclib |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |